![]() Hematopoietic stem cell transplant (HSCT) recipients and CAR T-cell therapy recipients are recommended to consult with their physician regarding COVID-19 vaccine spacing.A shortened interval is not permitted for the other eligible groups. A shortened interval of at least 3 calendar months between the previous bivalent booster dose (or infection) and the additional bivalent booster dose will be permitted for residents of long-term care facilities and other congregate care living settings to administer the additional dose to as many people as possible in a timely manner.A longer interval leads to a better immune response against COVID-19 infection that is expected to last longer. At least 6 months since the last dose or most recent COVID-19 infection.Individuals taking certain medications for autoimmune diseases including rituximab, ocrelizumab, ofatumumab and methotrexate.Recipients of active cancer treatment (chemotherapy, immunotherapy or targeted therapies), excluding those receiving only hormonal therapy, radiation therapy or surgery.Individuals with chronic kidney disease receiving regular dialysis.Transplant recipients, including solid organ and hematopoietic stem cell transplants.Recipients of immunosuppressive therapies (for example, anti-B cell therapies, high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents).Individuals with advanced untreated HIV infection or acquired immunodeficiency syndrome (AIDS). Individuals with moderate to severe primary immunodeficiency (for example, DiGeorge syndrome, Wiskott-Aldrich syndrome).Recipients of chimeric antigen receptor (CAR) T-cell therapy.Adults 18 years and older with the following eligible immunocompromising conditions:. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |